Sialorrhea Clinical Trial
Official title:
A Phase 3, Long-Term, Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects
Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.
Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea. The primary goal is to determine the long-term safety and tolerability of MYOBLOC (administered intraglandularly as single total dose of 3,500 Units) treatments every 13 weeks over a maximum possible duration of 1 year in adult subjects with troublesome sialorrhea. The secondary goal is to assess the magnitude of therapeutic response of MYOBLOC (administered intraglandularly as a single total dose of 3,500 Units) using effectiveness assessments performed at intervals after treatments every 13 weeks over a maximum possible duration of 1 year. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02425176 -
Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05164367 -
Pharmacokinetics of Atropine Oral Gel
|
Early Phase 1 | |
| Not yet recruiting |
NCT05097079 -
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT01994109 -
Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects
|
Phase 3 | |
| Active, not recruiting |
NCT01489904 -
Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04873115 -
Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
|
Phase 4 | |
| Withdrawn |
NCT03704168 -
Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders
|
N/A | |
| Completed |
NCT01653132 -
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
|
Phase 2 | |
| Completed |
NCT00491894 -
Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions
|
Phase 3 | |
| Completed |
NCT04197037 -
Prevalence of Sialorrhea in Patients Treated With Clozapine
|
||
| Completed |
NCT06101160 -
Botulinum Toxin Injection for Sialorrhea in Cerebral Palsy
|
||
| Completed |
NCT01118143 -
Oral Health Literacy Tailored Communication
|
N/A | |
| Completed |
NCT01191398 -
Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation
|
N/A | |
| Recruiting |
NCT02382198 -
Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease
|
Phase 2 | |
| Completed |
NCT00125203 -
Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2/Phase 3 | |
| Completed |
NCT02613494 -
Clozapine-induced Hypersalivation - Feasibility Trial
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03747536 -
Ipratropium Bromide Spray as Treatment for Sialorrhea in Children
|
Phase 2 | |
| Completed |
NCT01551940 -
Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea
|
Phase 2 | |
| Completed |
NCT00683891 -
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
|
N/A |